Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forty Seven Raises $75 Million For Possible 'Universal' Cancer Therapy

This article was originally published in Start Up

Executive Summary

Forty Seven Inc. spun out of Stanford with a $75 million Series A and an immuno-oncology development program that's already in the clinic with data expected later this year.

Advertisement

Related Content

Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition
Science Matters: CD47 Pathway Links To CV Disease, New Drug Development Opportunities
IN VIVO’s Deals Of The Month: February 2016

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel